** Berenberg analysts outline expectations for obesity drug updates during American Diabetes Association meeting on June 20-23
** Investor interest in obesity stocks waned after Novo Nordisk's NOVOb.CO CagriSema disappointed, but event could revive it with new data - Berenberg
** Adds, Eli Lilly's LLY.N orforglipron also in spotlight
** Detailed CagriSema data can highlight weight loss potential and other parameters that could help Novo move further off its lows, they say
** YTD, NOVOb is down 16.7%
** Adds, if orforglipron confirmed safe, will increase investor confidence of a 2026 launch
** Several companies to present data on amylin, and if positive, Berenberg expects a positive effect for Zealand ZELA.CO due to its high exposure
** Data on Amgen's AMGN.O MariTide, Lilly's bimagrumab and Roche's ROG.S CT-388 are also on Berenberg's radar
** It will also watch updates from BrightGene 688166.SS on BGM0504, Lilly/Innovent on mazdutide in diabetes and Terns Pharma TERN.O on oral GLP-1, TERN-601
(Reporting by Anna Pruchnicka)
((anna.pruchnicka@tr.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。